AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice

Atherosclerosis

Volumn 210, Issue 2, 2010, Pages 430-437

  Sasaki, Takeshi ^a,b   Kuzuya, Masafumi ^b   Nakamura, Kae ^b   Cheng, Xian Wu ^b   Hayashi, Taiju ^a   Song, Haizhen ^b   Hu, Lina ^b   Okumura, Kenji ^b   Murohara, Toyoaki ^b   Iguchi, Akihisa ^b   Sato, Kohji ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 receptor; Apolipoprotein E deficient mouse; Cathepsin S; Olmesartan; Oxidative stress; Plaque vulnerability

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; APOLIPOPROTEIN E; CATHEPSIN S; COLLAGEN; ELASTIN; MESSENGER RNA; OLMESARTAN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; HEART RATE; HISTOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIPID DIET; MACROPHAGE; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANGIOTENSIN I; ANIMAL FEED; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CATHEPSINS; COLLAGEN; DIETARY FATS; ELASTIN; IMIDAZOLES; MACROPHAGES; MALE; MICE; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 77953231164     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.12.031     Document Type: Article

References (40)

1. Katagiri H., Yamada T., Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007, 101:27-39.
2. Kuzuya M., Iguchi A. Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 2003, 10:275-282.
3. Liu J., Sukhova G.K., Sun J.S., et al. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:1359-1366.
4. Garcia-Touchard A., Henry T.D., Sangiorgi G., et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 2005, 25:1119-1127.
5. Lutgens S.P., Cleutjens K.B., Daemen M.J., Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007, 21:3029-3041.
6. Shi G.P., Munger J.S., Meara J.P., Rich D.H., Chapman H.A. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992, 267:7258-7262.
7. Maciewicz R.A., Etherington D.J. A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen. Biochem J 1998, 256:433-440.
8. Cheng X.W., Obata K., Kuzuya M., et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 2006, 48:979-987.
9. Cheng X.W., Kuzuya M., Nakamura K., et al. Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. Am J Pathol 2006, 168:685-694.
10. Sukhova G.K., Shi G.-P., Simon D.I., Chapman H.A., Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998, 102:576-583.
11. Cheng X.W., Kuzuya M., Sasaki T., et al. Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries. Am J Pathol 2004, 164:243-251.
12. Sukhova G.K., Zhang Y., Pan J.H., et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003, 111:897-906.
13. Rodgers K.J., Watkins D.J., Miller A.L., et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006, 26:851-856.
14. Lutgens E., Lutgens S.P., Faber B.C., et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006, 113:98-107.
15. Vaughan D.E. AT1 receptor blockade and atherosclerosis: hopeful insights into vascular protection. Circulation 2000, 101:1496-1497.
16. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000, 342:145-153.
17. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA). Lancet 2003, 362:782-788.
18. Fliser D., Buchholz K., Haller H. European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. 1. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110:1103-1107.
19. Weiss D., Kools J.J., Taylor W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001, 103:448-454.
20. Wassmann S., Czech T., van Eickels M., et al. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004, 110:3062-3067.
21. Browatzki M., Larsen D., Pfeiffer C.A., et al. Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J Vasc Res 2005, 42:415-423.
22. Wang M., Zhang J., Spinetti G., et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 2005, 167:1429-1442.
23. Guo R.W., Yang L.X., Wang H., Liu B., Wang L. Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regul Pept 2008, 147:37-44.
24. Cipollone F., Fazia M., Iezzi A., et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004, 109:1482-1488.
25. Liang C., Wu Z.G., Ding J., et al. Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages. Acta Pharmacol Sin 2004, 25:1426-1432.
26. Suganuma E., Babaev V.R., Motojima M., et al. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. J Am Soc Nephrol 2007, 18:2311-2319.
27. Fukuda D., Sata M., Ishizaka N., Nagai R. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2008, 28:90-96.
28. Tsuda M., Iwai M., Li J.M., et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005, 45:545-551.
29. Liu J., Sukhova G.K., Yang J.T., et al. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. Atherosclerosis 2006, 184:302-311.
30. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251-262.
31. Chen J., Li D., Schaefer R.F., Mehta J.L. Inhibitory effect of candesartan and rosuvastatin on cd40 and mmps expression in apo-e knockout mice: novel insights into the role of ras and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol 2004, 44:446-452.
32. Luchtefeld M., Grote K., Grothusen C., et al. Angiotensin II induces mmp-2 in a p47phox-dependent manner. Biochem Biophys Res Commun 2005, 328:183-188.
33. Cheng X.W., Murohara T., Kuzuya M., et al. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol 2008, 173:358-369.
34. Rueckschloss U., Quinn M.T., Holtz J., Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002, 22:1845-1851.
35. Kato Y., Mori Y., Makino Y., et al. Formation of N&supe{open};-(hexanonyl)lysine in protein exposed to lipid hydroperoxide. A plausible marker for lipid hydroperoxide-derived protein modification. J Biol Chem 1999, 274:20406-20414.
36. Fukuchi Y., Miura Y., Nabeno Y., et al. Immunohistochemical detection of oxidative stress biomarkers, dityrosine and N(epsilon)-(hexanoyl)lysine, and C-reactive protein in rabbit atherosclerotic lesions. J Atheroscler Thromb 2008, 15:185-192.
37. Samokhin A.O., Wong A., Saftig P., Brömme D. Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice. Atherosclerosis 2008, 200:58-68.
38. Dol F., Martin G., Staels B., et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2001, 38:395-405.
39. Tummala P.E., Chen X.L., Sundell C.L., et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999, 100:1223-1229.
40. Pueyo M.E., Gonzalez W., Nicoletti A., et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000, 20:645-651.